MUC1 and idiopathic pulmonary fibrosis: For patients with IPF on antifibrotic treatments, prior studies have described the potential utility of serially measured blood levels of mucin-1/KL-6 in longitudinally assessing or predicting the therapeutic response [38,39,40,41,42].